STOCK TITAN

[Form 4] UNITEDHEALTH GROUP INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

John H. Noseworthy, M.D., a director of UnitedHealth Group Inc. (UNH), reported a non‑derivative acquisition on 09/23/2025. The filing shows 39 shares of Common Stock were acquired at a reported price of $0, described as dividend equivalents paid on vested deferred stock units that are immediately vested and subject to the same terms as the underlying deferred stock units. After the transaction, Dr. Noseworthy beneficially owned 6,432 shares of UNH. The Form 4 was signed by an attorney‑in‑fact on 09/25/2025.

John H. Noseworthy, M.D., un direttore di UnitedHealth Group Inc. (UNH), ha riferito un'acquisizione non derivativa il 23/09/2025. La comunicazione indica che sono state acquisite 39 azioni di azioni ordinarie al prezzo riportato di $0, descritto come equivalenti di dividendi pagati su unità azionarie differite vestite che sono immediatamente vestite e soggette agli stessi termini delle unità azionarie differite sottostanti. Dopo l'operazione, il dottor Noseworthy detiene in modo beneficiario 6.432 azioni UNH. Il modulo 4 è stato firmato da un procuratore‑in‑fatto il 25/09/2025.

John H. Noseworthy, M.D., director de UnitedHealth Group Inc. (UNH), informó de una adquisición no derivada el 23/09/2025. El expediente muestra que se adquirieron 39 acciones de acciones ordinarias a un precio reportado de $0, descrito como equivalentes de dividendos pagados sobre unidades de acciones diferidas vestidas que se vuelven efectivas de inmediato y sujetas a los mismos términos que las unidades de acciones diferidas subyacentes. Después de la operación, el Dr. Noseworthy posee de forma beneficiosa 6,432 acciones de UNH. El Formulario 4 fue firmado por un apoderado el 25/09/2025.

존 H. 노즈워스-피(M.D.), UnitedHealth Group Inc. (UNH)의 이사인 닥터는 2025년 9월 23일 비파생 취득을 보고했습니다. 이 서류에는 39주의 보통주가 보고된 가격 $0에 취득되었다고 나와 있는데, 이는 즉시 귀속되는 연금형 주식단위에 대해 지급된 배당 수당으로서, 기초가 되는 지연 주식 단위와 동일한 조건에 따라 적용됩니다. 거래 후 노즈워스피 박사는 UNH의 6,432주를 유리하게 보유하게 되었습니다. Form 4는 2025년 9월 25일에 대리인에 의해 서명되었습니다.

John H. Noseworthy, M.D., administrateur de UnitedHealth Group Inc. (UNH), a signalé une acquisition non dérivée le 23/09/2025. Le dossier montre que 39 actions ordinaires ont été acquises au prix déclaré de $0, décrit comme des équivalents de dividendes versés sur des unités d’actions différées acquises immédiatement et soumises aux mêmes conditions que les unités d’actions différées sous-jacentes. Après la transaction, le Dr Noseworthy détenait de manière bénéficiaire 6 432 actions d’UNH. Le Formulaire 4 a été signé par un mandataire le 25/09/2025.

John H. Noseworthy, M.D., ein Direktor der UnitedHealth Group Inc. (UNH), meldete am 23.09.2025 eine nicht ableitende Akquisition. Die Einreichung zeigt, dass 39 Anteile der Stammaktien zu einem gemeldeten Preis von $0 erworben wurden, beschrieben als Dividendengegenwerte, die auf vesting deferred stock units gezahlt werden und sofort vesten und denselben Bedingungen wie die zugrunde liegenden deferred stock units unterliegen. Nach der Transaktion hielt Dr. Noseworthy vorteilhaft 6.432 Anteile von UNH. Das Formular 4 wurde am 25.09.2025 von einem Bevollmächtigten unterzeichnet.

جون إتش. نوشوورثي، دكتور في الطب، عضو مجلس إدارة مجموعة UnitedHealth Group Inc. (UNH)، قدم تقريراً عن استحواذ غير مشتق في 23/09/2025. تُظهر الوثيقة أن 39 سهماً من الأسهم العادية تم اكتسابها بسعر محكوم $0، ووصف ذلك باعتبارها مكافئات للأرباح المدفوعة على وحدات أسهم مؤجلة مُكتسبة فوراً وخاضعة لنفس شروط وحدات الأسهم المؤجلة الأساسية. بعد الصفقة، أصبح للدكتور نوشوفورثي ملكية مستفيدة قدرها 6,432 سهماً من UNH. تم توقيع النموذج 4 من قبل وكيل قانوني في 25/09/2025.

约翰·H·诺斯沃斯菲,医学博士,担任联合健康集团公司(UNH)的董事,已于2025年9月23日披露了一项非衍生性收购。 文件显示以披露价格 $0 购买了 39 股普通股,描述为对已归属且立即归属的延期股票单位所支付的股息等价物,与基础延期股票单位的条款相同。交易完成后,诺斯沃斯菲博士实际受益持有 UNH 的 6,432 股。表格4由代理律师于 2025年9月25日签署。

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Director received 39 dividend‑equivalent shares; small, routine equity accrual with no indicated cash purchase.

The filing reports 39 shares issued as dividend equivalents on vested deferred stock units and a post‑transaction beneficial ownership of 6,432 shares. The acquisition is recorded at a $0 price, consistent with equity grants or dividend‑equivalent distributions rather than an open‑market purchase. Given the small share count relative to a large‑cap issuer, this transaction is routine compensation administration and not material for valuation or control considerations.

TL;DR: Routine insider reporting of vested deferred stock unit dividend equivalents; disclosure aligns with Section 16 requirements.

The Form 4 discloses the director status of the reporting person and classifies the acquisition as dividend equivalents tied to vested deferred stock units. The description clarifies immediate vesting and identical terms to the underlying units, which is standard for deferred equity compensation. The filing was executed by an attorney‑in‑fact, indicating timely administrative handling. No governance or control change is evident from the disclosed amounts.

John H. Noseworthy, M.D., un direttore di UnitedHealth Group Inc. (UNH), ha riferito un'acquisizione non derivativa il 23/09/2025. La comunicazione indica che sono state acquisite 39 azioni di azioni ordinarie al prezzo riportato di $0, descritto come equivalenti di dividendi pagati su unità azionarie differite vestite che sono immediatamente vestite e soggette agli stessi termini delle unità azionarie differite sottostanti. Dopo l'operazione, il dottor Noseworthy detiene in modo beneficiario 6.432 azioni UNH. Il modulo 4 è stato firmato da un procuratore‑in‑fatto il 25/09/2025.

John H. Noseworthy, M.D., director de UnitedHealth Group Inc. (UNH), informó de una adquisición no derivada el 23/09/2025. El expediente muestra que se adquirieron 39 acciones de acciones ordinarias a un precio reportado de $0, descrito como equivalentes de dividendos pagados sobre unidades de acciones diferidas vestidas que se vuelven efectivas de inmediato y sujetas a los mismos términos que las unidades de acciones diferidas subyacentes. Después de la operación, el Dr. Noseworthy posee de forma beneficiosa 6,432 acciones de UNH. El Formulario 4 fue firmado por un apoderado el 25/09/2025.

존 H. 노즈워스-피(M.D.), UnitedHealth Group Inc. (UNH)의 이사인 닥터는 2025년 9월 23일 비파생 취득을 보고했습니다. 이 서류에는 39주의 보통주가 보고된 가격 $0에 취득되었다고 나와 있는데, 이는 즉시 귀속되는 연금형 주식단위에 대해 지급된 배당 수당으로서, 기초가 되는 지연 주식 단위와 동일한 조건에 따라 적용됩니다. 거래 후 노즈워스피 박사는 UNH의 6,432주를 유리하게 보유하게 되었습니다. Form 4는 2025년 9월 25일에 대리인에 의해 서명되었습니다.

John H. Noseworthy, M.D., administrateur de UnitedHealth Group Inc. (UNH), a signalé une acquisition non dérivée le 23/09/2025. Le dossier montre que 39 actions ordinaires ont été acquises au prix déclaré de $0, décrit comme des équivalents de dividendes versés sur des unités d’actions différées acquises immédiatement et soumises aux mêmes conditions que les unités d’actions différées sous-jacentes. Après la transaction, le Dr Noseworthy détenait de manière bénéficiaire 6 432 actions d’UNH. Le Formulaire 4 a été signé par un mandataire le 25/09/2025.

John H. Noseworthy, M.D., ein Direktor der UnitedHealth Group Inc. (UNH), meldete am 23.09.2025 eine nicht ableitende Akquisition. Die Einreichung zeigt, dass 39 Anteile der Stammaktien zu einem gemeldeten Preis von $0 erworben wurden, beschrieben als Dividendengegenwerte, die auf vesting deferred stock units gezahlt werden und sofort vesten und denselben Bedingungen wie die zugrunde liegenden deferred stock units unterliegen. Nach der Transaktion hielt Dr. Noseworthy vorteilhaft 6.432 Anteile von UNH. Das Formular 4 wurde am 25.09.2025 von einem Bevollmächtigten unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Noseworthy John H

(Last) (First) (Middle)
C/O UNITEDHEALTH GROUP INCORPORATED
1 HEALTH DRIVE

(Street)
EDEN PRAIRIE MN 55344

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
UNITEDHEALTH GROUP INC [ UNH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/23/2025 A 39(1) A $0 6,432 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents dividend equivalents paid on vested deferred stock units. The dividend equivalents are immediately vested and are subject to the same terms as the underlying deferred stock units.
Remarks:
Faraz A. Choudhry, Attorney-in-Fact for John H. Noseworthy M.D. 09/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did UNH director John H. Noseworthy report on Form 4?

The Form 4 reports acquisition of 39 shares of UNH common stock on 09/23/2025, recorded as dividend equivalents on vested deferred stock units.

Was any cash paid for the 39 shares reported by John H. Noseworthy?

No cash was reported; the price is listed as $0, reflecting dividend equivalents rather than an open‑market purchase.

How many UNH shares did John H. Noseworthy beneficially own after the transaction?

After the reported transaction, he beneficially owned 6,432 shares of UNH.

What is the nature of the dividend equivalents reported in the Form 4?

The filing states the dividend equivalents were paid on vested deferred stock units, are immediately vested, and are subject to the same terms as the underlying units.

Who signed the Form 4 for John H. Noseworthy and when?

The Form 4 was signed by Faraz A. Choudhry, Attorney‑in‑Fact for John H. Noseworthy on 09/25/2025.
Unitedhealth Gp

NYSE:UNH

UNH Rankings

UNH Latest News

UNH Latest SEC Filings

UNH Stock Data

311.62B
897.88M
0.82%
86.64%
1.32%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
EDEN PRAIRIE